Tiapridal

Quick links to important sections

Tiapridal

Selected form

Treatment option: Pain

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tiapridal

Property Description
Active ingredient Tiapride (Tiapride Hydrochloride)
Form Tablet, Injectable Solution, Oral Solution/Drops
Pharmacological class Neuroleptic Agent / Atypical Antipsychotic
General purpose Behavior Stabilization and Muscle Activity Management
Origin Synthetic Benzamide Derivative

What is Tiapridal and What Type of Drug is it?

Tiapridal is a pharmaceutical product containing the single active ingredient, Tiapride. This medication is formally classified as a neuroleptic agent, which is clinically recognized for its ability to modulate nerve function; it is more specifically known as an atypical antipsychotic.

The chemical structure of Tiapride is entirely synthetic, placing it within the defined benzamide derivative group. This classification identifies its role as a focused central nervous system modulator. Tiapridal is often prescribed for adult and geriatric patient groups due to its established efficacy profile in these demographics.

What Forms is Tiapridal Available In?

The product is formulated in several versatile dosage forms, a feature differentiating it from single-form medications. These include conventional oral tablets and liquid preparations for internal use, such as the oral solution or drops, as well as an injectable solution for parenteral administration.

Each formulation contains Tiapride as the exclusive active component. Under the Anatomical Therapeutic Chemical (ATC) code N05AL03, it is designated as a benzamide antipsychotic. This categorization describes the drug's primary neurochemical function.

How Does Tiapride Selectively Modulate Brain Activity?

Tiapride achieves its action by functioning as a selective antagonist (blocker) of specific receiving sites in the brain, notably the dopamine D2 and D3 receptors. This mechanism of action is significant because Tiapride demonstrates a high degree of regional selectivity.

This process of selective dopamine modulation is the pharmacological foundation for the drug's general therapeutic effects. By helping to restore neurochemical equilibrium in specific parts of the central nervous system, Tiapride assists in the stabilization of behavior and the management of involuntary muscle activity.

What side effects are possible with Tiapridal?

Officially Documented Safety Profile of Tiapridal (Tiapride)

Tiapridal's official safety profile, as documented in regulatory sources, is categorized by the frequency and the physiological system affected. This ensures transparent communication of potential risks without providing clinical advice or instructions for use.

Common Adverse Reactions

Reactions classified as common (affecting up to 1 in 10 individuals) often relate to the central nervous system. These include somnolence (drowsiness), headache, dizziness, and general fatigue. Movement disorders are frequently documented, notably Parkinsonism (a drug-induced tremor and rigidity) and akathisia (restlessness). Endocrine and metabolic effects like hyperprolactinaemia (increased prolactin levels) and weight gain are also listed as common.

Serious Adverse Reactions and Safety Constraints

The most serious events are classified as rare (affecting up to 1 in 10,000 individuals). These critical risks include the potentially fatal cardiac condition Torsades de Pointes (a type of ventricular arrhythmia) and Neuroleptic Malignant Syndrome (NMS). The drug is contraindicated in individuals with a rare adrenal gland tumour known as phaeochromocytoma, and in those with known prolactin-dependent tumours.

Population-Specific and Time-Related Notes

Specific caution is warranted for older adults due to an increased risk of confusion and falls associated with extrapyramidal effects. For patients with renal impairment, a reduced ability to clear the drug elevates the risk of adverse reactions. The label notes that extrapyramidal symptoms may appear more frequently at the start of treatment or during dose escalation, while tardive dyskinesia is a risk associated with long-term exposure.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

Overdose of Tiapridal (Tiapride) is associated with several serious clinical manifestations documented in official regulatory labeling. These effects generally relate to the central nervous system (CNS) and the cardiovascular system.

Documented Manifestations and Serious Risks

Category Documented Manifestation
CNS Effects Drowsiness, sedation, extrapyramidal symptoms, and coma.
Cardiovascular Risk Hypotension, QT-interval prolongation, and the potential for severe ventricular arrhythmias, notably Torsades de pointes.

Emergency Response and Management

In the event of a suspected overdose, the official instruction is to seek emergency medical treatment or contact a doctor immediately.

Management is primarily symptomatic and supportive, as there is no specific antidote for Tiapride. Required procedures include close clinical and continuous cardiac monitoring due to the risk of life-threatening arrhythmias. Procedures such as gastric lavage or the administration of activated charcoal combined with a laxative may be considered by healthcare professionals for severe, recent intoxications. Tiapride is only moderately dialyzed, limiting the effectiveness of haemodialysis.

Therapeutic Uses of Tiapridal

What Tiapridal Treats: Main Uses and Benefits

Tiapridal is used in the context of a variety of neurological and psychiatric disorders. It plays a role in managing conditions characterized by periods of heightened symptoms and is commonly used across domains where additional symptomatic support is needed.

The therapeutic benefit may assist in managing pronounced symptoms such as agitation and aggression, various forms of involuntary motor movements (dyskinesias and tics), and the severe excitement and tremor associated with alcohol withdrawal syndrome.

The medication is applied to address symptom clusters that may become intense or disruptive, especially in contexts like geriatric care or during acute abstinence.

Quick Fact: Relief for Involuntary Movements

The medication may assist with managing uncontrollable movements, such as chronic motor tics or drug-induced dyskinesias, reducing the noticeable functional strain they create.

Regulatory References

  1. MHRA safety update on Tiapride's established uses

Eligibility and Restrictions for Use

Who Can and Cannot Use Tiapridal?

Eligibility for Tiapridal (Tiapride) is strictly defined by government regulatory documents, establishing absolute prohibitions for certain populations and conditional use for others.

Eligibility Scope Official Regulatory Status
Populations for whom use is contraindicated Patients with known hypersensitivity to Tiapride, prolactin-dependent tumors (e.g., prolactinoma), pheochromocytoma, or those concurrently receiving levodopa or non-antiparkinsonian dopaminergic agonists.
Age-related eligibility rules Children and adolescents (under 18 years) are not recommended for use, as safety and efficacy are not clinically established. Use in older adults requires extreme caution and often dose reduction due to increased risk factors.
Condition-specific eligibility rules Patients with renal impairment must use the medicine with caution, and the dose must be reduced due to the drug's primary excretion route. Caution is also required for patients with risk factors for QT interval prolongation (e.g., bradycardia) or a history of epilepsy (due to lowered seizure threshold).
Pregnancy and lactation eligibility status Use is not recommended during pregnancy, particularly in the third trimester (risk of neonatal symptoms), or while breastfeeding, as the drug is excreted in breast milk.

These official statements delineate who may and may not use the medicine, limiting the patient population to those for whom use is supported by regulatory standards, while excluding populations with absolute contraindications or insufficient safety data.

What should I know about interactions with other medicines?

Contraindicated Combinations

Formal restrictions exist for combining Tiapridal with certain medicinal products. Co-administration is strictly contraindicated with a defined group of QT-prolonging agents (e.g., Pimozide, Moxifloxacin) due to the documented risk of additive effects on cardiac rhythm. Additionally, specific Dopaminergic Agonists (e.g., Cabergoline, Quinagolide) are contraindicated due to documented reciprocal antagonism of effects.

Interactions Requiring Caution

Combining Tiapridal with various Central Nervous System (CNS) depressants (including benzodiazepines, barbiturates, or sedative antidepressants) results in a documented potentiation of the sedative effect. This includes the restriction that co-administration with alcohol or alcohol-containing medicines must be avoided. Other combinations require specific caution due to increased arrhythmia risk, such as with Bradycardia-Inducing Agents and Potassium-Lowering Agents (e.g., certain diuretics or stimulant laxatives), which may increase the risk of ventricular arrhythmias.

Clearance and Population-Specific Notes

Since Tiapridal is primarily eliminated unchanged by the kidneys, official labeling notes that its use in patients with impaired renal function carries a documented risk of reduced clearance and resulting drug accumulation. For elderly patients, official information indicates an increased risk of enhanced sedative effects when combined with interacting CNS-acting substances.

Mechanism of Action

Tiapridal is a substituted benzamide derivative that functions as a selective antagonist of the Dopamine D2 and D3 receptors in the central nervous system. Its primary molecular action involves binding to and blocking these postsynaptic receptors, particularly within limbic brain regions, which include the nucleus accumbens and septum. This regional selectivity is a key characteristic of its pharmacodynamic profile.

Antagonism of the D2-like receptor family (D2, D3) prevents the endogenous neurotransmitter dopamine from activating the receptor. Since the D2-like receptors are coupled to the inhibitory G protein (Galpha i/o), their blockade results in a reduction of the inhibitory signal that dopamine normally exerts on the target neurons.

This leads to a modulation of dopaminergic pathways, increasing the overall extracellular levels of dopamine in certain brain areas, such as the nucleus accumbens and striatum, which is thought to be a compensatory reflection of the blockade of postsynaptic receptors. The resulting neurochemical changes modify signal transmission within circuits regulating motor and emotional processing.

Dosage and Administration Information

Tiapridal (tiapride) should be taken exactly as prescribed by your healthcare provider. Your doctor will determine the appropriate dose and duration of treatment based on your condition, age, and kidney function.

It is important to follow the prescribed dosing schedule and never stop taking Tiapridal without consulting your doctor, as this could lead to a worsening of your symptoms.

Administration and Dosing

  • Oral Formulations: Tiapridal is most commonly available as tablets and an oral solution. Tablets can generally be taken with or without food. However, in some contexts, it may be advised to take the tablet after meals to reduce gastrointestinal upset.
  • General Adult Dosing: For adults, the typical oral daily dosage is often between 100 to 300 mg, usually divided and taken 2 to 3 times per day.
  • Special Populations: Lower starting doses are generally recommended for elderly patients and those with impaired kidney function (renal impairment), as tiapride is mainly eliminated through the kidneys. A reduced dosage is necessary to prevent accumulation of the medicine in the body.
Condition Typical Daily Dose Range (Adults)
Agitation and Aggressiveness (Elderly) 100–300 mg
Alcohol Withdrawal Syndrome 300 mg (under supervision)
Dyskinetic Disorders 300–800 mg

Handling Missed or Extra Doses

  • Missed Dose: If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take a double dose to make up for the missed one.
  • Overdose: If you accidentally take more than your prescribed dose, seek immediate medical attention or contact your doctor or pharmacist.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence for Acute Symptom Management

Studies have evaluated the drug for use in managing agitation, aggression, and alcohol withdrawal syndrome. Research has examined the onset of symptom reduction, particularly in elderly populations and in cases of acute alcohol withdrawal.

  • Research explored the statistical change in symptom scores, with some studies showing an improvement over placebo in reducing restlessness and aggression in patients with cognitive impairment.
  • Studies reviewed the administration of this medication according to prescribed dosage limits. Research findings concerning the safety profile for short-term use were documented, often suggesting a lower incidence of motor-related side effects compared to some conventional antipsychotics.

Research has also investigated the drug's role in movement disorders, such as tardive dyskinesia and Huntington’s disease, though evidence remains limited for its broad application in all chronic neurological outcomes.


Combination Therapy: Research Overview

Studies evaluated whether combining the drug with certain other medications, such as non-opioid pain relievers or anticonvulsants (like carbamazepine), was associated with different therapeutic outcomes, particularly in alcohol withdrawal syndrome (AWS).

  • Some research examined the potential of combination therapy to influence the severity of AWS symptoms, including tremor and hyperhidrosis, compared to monotherapy.
  • Research findings were mixed regarding whether this approach led to a statistically greater effect on all measured outcomes when compared to established standard treatments.

Side Effects and Tolerability: Research Findings

Studies have systematically recorded adverse events and tolerability profiles across different populations, particularly focusing on the elderly and patients with movement disorders.

  • Studies documented the reported severity of the most common side effects, which include drowsiness, dizziness, and gastrointestinal issues. Research has explored the occurrence and duration of these effects.
  • Research has also investigated the drug's effects in individuals with pre-existing liver or renal conditions, highlighting that renal impairment may extend the drug's elimination half-life.

Frequently Asked Questions (FAQ)

Common questions about Tiapridal (FAQ)

Q: How quickly can I expect Tiapridal to start working?

A: The amount of time required for Tiapridal to fully show its therapeutic effects is not clinically established in official documents. Studies have primarily focused on the short-term use of the medication for acute symptoms, rather than providing a definitive timeline for onset. Individual response to the medication may vary depending on the prescribed dosage and the condition being managed.


Q: Can Tiapridal be taken long-term?

A: Tiapridal is officially approved for short-term treatment (such as less than 4 weeks) for certain acute indications, like episodes of aggression. Official documents also mention that tardive dyskinesia—a type of involuntary movement disorder—is a documented risk associated with long-term exposure. The decision regarding extended use is based on ongoing clinical assessment.


Q: What kind of monitoring is typically needed when taking Tiapridal?

A: Official warnings note that because Tiapridal is cleared primarily by the kidneys, close monitoring of kidney function tests is often necessary, especially for patients with renal impairment. Additionally, due to the documented risk of effects on heart rhythm (QTc prolongation), an ECG monitoring may be assessed based on individual patient risk factors.


Q: What are the signs of a serious side effect from Tiapridal?

A: Official safety documents list critical risks such as Neuroleptic Malignant Syndrome (NMS) and a serious heart rhythm issue called Torsades de Pointes. Symptoms of NMS can include fever, muscle stiffness, and changes in consciousness. Signs of Torsades de Pointes may include heart palpitations, dizziness, or fainting.


Q: Are there warnings about Tiapridal for people with Parkinson's disease?

A: Tiapridal is contraindicated (strictly forbidden) for use with levodopa and certain other dopaminergic agonists used in the treatment of Parkinson’s disease. Official documents also note that the drug can induce extrapyramidal symptoms (movement problems), which resemble symptoms of Parkinson's disease.


Q: Is it okay to drive or operate machinery while on Tiapridal?

A: Official product information advises that patients should be cautious when performing skilled tasks like driving or operating machinery. This warning is based on the common side effects of the medication, which can include fatigue, dizziness, or drowsiness, which may impair alertness.


Q: What is the general duration of treatment with Tiapridal?

A: The overall duration of treatment is determined by clinical factors specific to the condition being managed. Official guidance for certain acute conditions, such as episodes of agitation and aggressiveness in adults, often suggests short-term treatment (typically less than 4 weeks).


Q: Is Tiapridal a treatment for anxiety?

A: Tiapridal is primarily indicated for behavior stabilization, such as the management of agitation and aggression. While the official documents note the drug may have anxiolytic (anti-anxiety) and mood-stabilizing effects, it is not formally indicated as a primary treatment for anxiety disorders.


Q: Does Tiapridal interact with blood pressure medication?

A: Regulatory documents include a general warning about combining Tiapridal with antihypertensive agents (blood pressure medicines). Specifically, caution is advised when using it with Bradycardia-Inducing Agents (medicines that slow the heart rate) due to the documented risk of heart rhythm disturbances.


Q: Can Tiapridal be used for withdrawal symptoms?

A: Yes, Tiapridal is officially indicated for the management of the symptoms associated with alcohol withdrawal syndrome. These symptoms can include agitation, anxiety, and tremors, which are forms of withdrawal.


Q: Is there a risk of dependence or addiction with Tiapridal?

A: According to official drug information, Tiapridal is generally reported to have no habit-forming tendencies and no dependence concerns when used as prescribed.


Q: Does Tiapridal cause dry mouth?

A: Dry mouth (xerostomia) is documented in the official safety profile and is a reported potential side effect of Tiapridal.


Q: Does Tiapridal change mood?

A: The drug's mechanism of action involves modulating dopamine receptors, which are known to affect emotional processing. Tiapridal is used for behavior stabilization and may be noted in official documents for having mood-stabilizing effects in addition to its primary indications.


Q: Are there any specific liver or kidney concerns related to Tiapridal use?

A: Official warnings note that caution is required for patients with impaired renal (kidney) function, as the drug is primarily cleared by the kidneys, increasing the risk of accumulation. The product label does not typically highlight significant liver toxicity as a major concern.


Q: How soon after starting Tiapridal do side effects usually appear?

A: Official documents note that certain side effects, specifically extrapyramidal symptoms (like restlessness or tremor), may appear more frequently at the start of treatment or during a dose increase.


Q: Is Tiapridal used to treat tics?

A: Yes, official regulatory sources indicate that Tiapridal is used for the severe form of the tic disorder Tourette syndrome in specific age groups. This use is based on the drug's established effects on involuntary muscle and movement activity.


Q: Why is Tiapridal sometimes prescribed for people with dementia?

A: The drug is officially indicated for managing episodes of agitation and aggressiveness in adults with cognitive impairment. This includes patients whose behavioral disturbances are associated with conditions like dementia, and this use is supported by clinical studies.


Q: Does the time of day I take Tiapridal matter?

A: Official administration instructions often advise that the typical daily dosage is divided and taken 2 to 3 times per day. The tablets can generally be taken with or without food. The need for a specific time of day is typically related to maintaining a consistent schedule for the divided doses.

How should Tiapridal be stored and disposed of?

The storage and disposal of Tiapridal tablets are governed by specific regulatory requirements to ensure product stability and safety.

Official Storage Requirements

Requirement Category Condition Defined by Official Labeling
Maximum Temperature Store the medicinal product not above 30 C
Environmental Protection Protect from light and store away from direct moisture
Packaging Rules Keep the tablets in the original outer carton
Child Safety Must be stored out of the sight and reach of children

Disposal Instructions

Official documents indicate “No special requirements” for disposal. Any unused or expired Tiapridal tablets must be discarded in strict accordance with local regulatory requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tiapridal found in:

A-Z Index: